<DOC>
	<DOCNO>NCT00003784</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow monoclonal antibody therapy treat patient newly diagnose follicular non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>S9911 , Combination Chemotherapy Plus Monoclonal Antibody Therapy Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine 2 year failure free survival rate patient newly diagnose follicular lymphoma treat cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) follow iodine I 131 monoclonal antibody anti-B1 . II . Determine complete partial response rate patient therapy . III . Evaluate toxicity regimen patient . IV . Determine rate disappearance cell clonal ( 14 ; 18 ) /bcl2 rearrangement peripheral blood bone marrow therapy patient . OUTLINE : Patients receive cyclophosphamide IV 15 minute , doxorubicin IV , vincristine IV day 1 oral prednisone day 1-5 . Treatment repeat every 21 day 6 course . Within 4-8 week last course chemotherapy , patient achieve least partial response le 25 % bone marrow involvement begin immunotherapy . Patients receive unlabeled monoclonal antibody anti-B1 ( MOAB anti-B1 ) IV 1 hour , iodine I 131 MOAB anti-B1 IV 20 minute day 1 . This regimen repeat day 8 . Patients follow every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 80 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular nonHodgkin 's lymphoma No prior treatment Bulky stage II , stage III , stage IV Must express cluster differentiation antigen 20 ( CD20 ) antigen Bidimensionally measurable disease No Central Nervous System ( CNS ) involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Not specify Cardiovascular : No arrhythmia ( except sinus arrhythmia infrequent premature ventricular contraction ) No history impair cardiac status ( severe coronary artery disease , cardiomyopathy , congestive heart failure , serious arrhythmia Ejection fraction least normal Other : HIV negative No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior monoclonal antibody Chemotherapy : No prior chemotherapy lymphoma Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy lymphoma Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
</DOC>